Clinical Rheumatology

, Volume 28, Issue 12, pp 1359–1364 | Cite as

Pamidronate treatment in rheumatology practice: a comprehensive review

  • Gleb SlobodinEmail author
  • Itzhak Rosner
  • Joy Feld
  • Doron Rimar
  • Michael Rozenbaum
  • Nina Boulman
  • Majed Odeh
Review Article


Pamidronate, along with other bisphosphonates, has been used for treatment of bone pain secondary to malignant involvement or metastatic disease for years. Some data, however, have also accumulated on the utility of pamidronate in a variety of benign conditions frequently handled by rheumatologists. This study aims to review the available published data regarding the potential use of pamidronate in rheumatology practice. Methods include the review of relevant articles retrieved by a PUBMED search utilizing the index term “pamidronate”. All available randomized control trials, open trials, and case series, as well as properly reported case studies evaluating usage of pamidronate in rheumatic disorders, have been included in the literature review. The efficacy of pamidronate in patients with spondyloarthropathies; synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome; hypertrophic osteoarthropathy; osteoporotic vertebral fractures; chronic back pain due to disk disease or spinal stenosis; Charcot arthropathy; transient osteoporosis; and complex regional pain syndrome-I, has been demonstrated in more than 40 reports, the majority of which, however, were not controlled studies. In some of reviewed conditions, aside from providing analgesic relief, pamidronate may also have disease-modifying properties. While used in different doses in a variety of rheumatic disorders, pamidronate was generally reported to be well tolerated with an overall good safety profile. Pamidronate may represent an effective and safe choice for a spectrum of rheumatic patients, suffering from intractable musculoskeletal pain, unresponsive to traditionally recommended therapies. Large randomized, controlled studies examining the efficacy of pamidronate in the rheumatic conditions are urgently needed.


Pain Pamidronate Rheumatic disorder 





  1. 1.
    Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A et al (2002) A six-months randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46:766–773CrossRefPubMedGoogle Scholar
  2. 2.
    Maksymowych WP, Jhangri GS, LeClercq S, Skeith K, Yan A, Russell AS (1998) An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 25:714–717PubMedGoogle Scholar
  3. 3.
    Maksymowych WP, Lambert R, Jhangri GS, LeClercq S, Chiu P, Wong B et al (2001) Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 28:144–155PubMedGoogle Scholar
  4. 4.
    Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J (2003) Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 42:1018–1020CrossRefPubMedGoogle Scholar
  5. 5.
    Cairns AP, Wright SA, Taggart AJ, Coward SM, Wright GD (2005) An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 64:338–339CrossRefPubMedGoogle Scholar
  6. 6.
    Grover R, Shankar S, Aneja R, Marwaha V, Gupta R, Kumar A (2006) Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis 65:688–689CrossRefPubMedGoogle Scholar
  7. 7.
    Toussirot E, Le Huede G, Lohse A, Cedos J-P, Wendling D (2006) Transient efficacy of pulse pamidronate treatment in active spondyloarthropathies: an open study of 35 cases. Clin Exp Rheumatol 24:348PubMedGoogle Scholar
  8. 8.
    Maksymowych WP, Aaron S, Russell AS (2001) Treatment of refractory symphysitis pubis with intravenous pamidronate. J Rheumatol 28:2754–2757PubMedGoogle Scholar
  9. 9.
    Marshall H, Bromilow J, Thomas AL, Arden NK (2002) Pamidronate: a novel treatment for the SAPHO syndrome? Rheumatology 41:231–233CrossRefPubMedGoogle Scholar
  10. 10.
    Courtney PA, Hosking DJ, Fairbairn KJ, Deighton CM (2002) Treatment of SAPHO with pamidronate. Rheumatology 41:1196–1198CrossRefPubMedGoogle Scholar
  11. 11.
    Guignard S, Job-Deslandre C, Sayag-Boukris V, Kahan A (2002) Pamidronate treatment in SAPHO syndrome. Joint Bone Spine 69:392–396CrossRefPubMedGoogle Scholar
  12. 12.
    Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A (2004) SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology 43:658–661CrossRefPubMedGoogle Scholar
  13. 13.
    Valls-Roc M, Sanmarti M, Salles M, Holgado S, Olive A (2005) SAPHO syndrome and pamidronate revisited. Rheumatology 44:137CrossRefPubMedGoogle Scholar
  14. 14.
    Tehrani R (2005) SAPHO syndrome treated with pamidronate. Indian J Dermatol Venereol Leprol 71:273–275CrossRefPubMedGoogle Scholar
  15. 15.
    Solau-Gervais E, Soubrier M, Gerot I, Grange L, Puechal X, Sordet C et al (2006) The usefulness of bone remodeling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology 45:339–342CrossRefPubMedGoogle Scholar
  16. 16.
    Kerrison C, Davidson JE, Cleary AG, Beresford MW (2004) Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology 34:1246–1251CrossRefGoogle Scholar
  17. 17.
    Simm PJ, Allen RC, Zacharin MR (2008) Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis. J Pediatr 152:571–575CrossRefPubMedGoogle Scholar
  18. 18.
    Gleeson H, Wiltshire E, Briody J, Hall J, Chaitow J, Sillence D et al (2008) Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol 35:707–712PubMedGoogle Scholar
  19. 19.
    Guyot-Drouot M-H, Solau-Gervais E, Cortet B, Deprez X, Chastanet P, Cotten A et al (2000) Rheumatologic manifestations of pachydermoperiostosis and preliminary experience with bisphosphonates. J Rheumatol 27:2418–2423PubMedGoogle Scholar
  20. 20.
    Bhansali A, Singh R, Sriraam M, Bhadada S (2006) Pachydermoperiostitis and bisphosphonates. J Assoc Physicians India 54:340PubMedGoogle Scholar
  21. 21.
    Garske LA, Bell SC (2002) Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest 121:1363–1364CrossRefPubMedGoogle Scholar
  22. 22.
    Amital H, Applbaum YH, Vasiliev L, Rubinow A (2004) Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 23:330–332CrossRefPubMedGoogle Scholar
  23. 23.
    Speden D, Nicklason F, Francis H, Ward J (1997) The use of pamidronate in hypertrophic pulmonary osteoarthropathy. Aust N Z Med 27:307–310Google Scholar
  24. 24.
    Suzuma T, Sakurai T, Yoshimura G, Umemura T, Tamaki T, Yoshimasu T et al (2001) Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anticancer Drugs 12:731–734CrossRefPubMedGoogle Scholar
  25. 25.
    Abdulla AJ (2000) Use of pamidronate for acute pain relief following osteoporotic vertebral fractures. Rheumatology 39:567–568CrossRefPubMedGoogle Scholar
  26. 26.
    Gangji V, Appelboom T (1999) Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheum 18:266–267CrossRefGoogle Scholar
  27. 27.
    Armingeat T, Brondino R, Pham T, Legre V, Lafforgue P (2006) Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 17:1659–1665CrossRefPubMedGoogle Scholar
  28. 28.
    Laroche M, Cantogrel S, Jamard B, Constantin A, Zabranieski L, Cantagrel A et al (2006) Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. Clin Rheumatol 25:683–686CrossRefPubMedGoogle Scholar
  29. 29.
    Poujol D, Ristori JM, Dubost JJ, Soubrier M (2007) Efficacy of pamidronate in erosive degenerative disk disease: a pilot study. Joint Bone Spine 74:663–664CrossRefPubMedGoogle Scholar
  30. 30.
    Feld J, Rosner I, Avshovich N, Boulman N, Slobodin G, Rozenbaum M (2009) An open study of pamidronate in the treatment of refractory degenerative lumbar spinal stenosis. Clin Rheum 28(6):715–717CrossRefGoogle Scholar
  31. 31.
    Pappagallo M, Breuer B, Schneider A, Sperber K (2003) Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage 26:678–683CrossRefPubMedGoogle Scholar
  32. 32.
    Selby PL, Young MJ, Boulton AJ (1994) Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 11:28–31CrossRefPubMedGoogle Scholar
  33. 33.
    Naqvi A, Cuchacovich R, Saketkoo L, Espinosa LR (2008) Acute Charcot arthropathy successfully treated with pamidronate: long-term follow-up. Am J Med Sci 335:145–148CrossRefPubMedGoogle Scholar
  34. 34.
    Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM (2004) Bisphosphonates for the treatment of Charcot neuroarthropathy. J Foot Ankle Surgery 43:285–289CrossRefGoogle Scholar
  35. 35.
    Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR et al (2001) Bisphosphonates in the treatment og Charcot neuroarthropathy: a double-blind randomized control trial. Diabetologia 44:2032–2037CrossRefPubMedGoogle Scholar
  36. 36.
    Devogelaer JP, Dall'Armellina S, Huaux JP, Nagant de Deuxchaines C (1988) Dramatic improvement of intractable reflex sympathetic dystrophy syndrome by intravenous infusions of the second generation bisphosphonate APD [abstract]. J Bone Min Res 3(Suppl):S122Google Scholar
  37. 37.
    Brown SC, Jeavons M, Stinson J (2005) Effectiveness of pamidronate for treating intractable chronic neuropathic pain. Case report of two adolescents. Clin J Pain 21:549–552CrossRefPubMedGoogle Scholar
  38. 38.
    Maillefert JF, Chatard C, Owen S, Peere T, Tavernier C, Tebib J (1995) Treatment of refractory reflex sympathetic dystrophy with pamidronate. Ann Rheum Dis 54:687CrossRefPubMedGoogle Scholar
  39. 39.
    Cortet B, Flipo R-M, Coquerelle P, Duquesnoy B, Delcambre B (1997) Treatment of severe, recalcitrant reflex sympathetic dystrophy: assessment of efficacy and safety of the second generation bisphosphonate pamidronate. Clin Rheum 16:51–56CrossRefGoogle Scholar
  40. 40.
    Maillefert JF, Cortet B, Aho S (1999) Pooled results from 2 trials evaluating bisphosphonates in reflex sympathetic dystrophy. J Rheumatol 26:8Google Scholar
  41. 41.
    Kubalek I, Fain O, Paries J, Kettaneh A, Thomas M (2001) Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. Rheumatology 40:1394–1397CrossRefPubMedGoogle Scholar
  42. 42.
    Robinson JN, Sandom J, Chapman PT (2004) Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med 5:276–280CrossRefPubMedGoogle Scholar
  43. 43.
    Varenna M, Zucchi F, Binelli L, Failoni S, Gallazzi M, Sinigaglia L (2002) Intravenous pamidronate in the treatment of transient osteoporosis of the hip. Bone 31:96–101CrossRefPubMedGoogle Scholar
  44. 44.
    Petcu EB, Schug SA, Smith RH (2002) Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain. J Pain Symptom Manage 24:281–282CrossRefPubMedGoogle Scholar
  45. 45.
    Fulfaro F, Cassucio A, Ticozzi C, Ripamonti C (1998) The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78:157–169CrossRefPubMedGoogle Scholar
  46. 46.
    Bonabello A, Galmozzi MR, Bruzzese T, Zara GP (2001) Analgesic effect of biphosphonates in mice. Pain 91:269–275CrossRefPubMedGoogle Scholar
  47. 47.
    Bonabello A, Galmozzi MR, Canaparo R, Serpe L, Zara GP (2003) Long-term analgesic effect of clodronate in rodents. Bone 33:567–574CrossRefPubMedGoogle Scholar
  48. 48.
    Ceccini MG, Fleisch H (1990) Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouth mononuclear phagocyte lineage. J Bone Miner Res 5:1019–1027CrossRefGoogle Scholar
  49. 49.
    Pennanen N, Lapinjoki S, Urtti S, Monkkonen J (1995) Effect of liposomal and free biphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. Pharmacol Res 12:916–922CrossRefGoogle Scholar
  50. 50.
    Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR et al (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386–392CrossRefPubMedGoogle Scholar
  51. 51.
    Van Offel JF, Schuerwegh AJ, Bridts CH, Bracke PG, Stevens WJ, De Clerck LS (2001) Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate. Clin Exp Rheumatol 19:13–20PubMedGoogle Scholar
  52. 52.
    Carbone LD, Warrington KJ, Barrow KD, Pugazhenthi M, Watsky MA, Somes G et al (2006) Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles. Clin Exp Immunol 146:371–380CrossRefPubMedGoogle Scholar
  53. 53.
    Kunzmann V, Bauer E, Wilhelm M (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737–738CrossRefPubMedGoogle Scholar
  54. 54.
    Kunzmann V, Bauer E, Feurle J, Weiissinger F, Tony HP, Wilhelm M (2000) Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392PubMedGoogle Scholar
  55. 55.
    Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, Poccia F, Gessani S (2005) Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 174:252–260PubMedGoogle Scholar
  56. 56.
    Djokanovic N, Klieger-Grossmann C, Koren G (2008) Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 30:1146–1148PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  • Gleb Slobodin
    • 1
    Email author
  • Itzhak Rosner
    • 2
  • Joy Feld
    • 2
  • Doron Rimar
    • 2
  • Michael Rozenbaum
    • 2
  • Nina Boulman
    • 2
  • Majed Odeh
    • 1
  1. 1.Department of Internal Medicine ABnai Zion Medical Center and Ruth & Bruce Rappaport Faculty of Medicine, TechnionHaifaIsrael
  2. 2.Department of RheumatologyBnai Zion Medical Center and Ruth & Bruce Rappaport Faculty of Medicine, TechnionHaifaIsrael

Personalised recommendations